Send to

Choose Destination
Curr Drug Deliv. 2019 Nov 5. doi: 10.2174/1567201816666191106102020. [Epub ahead of print]

Recent avenues in Novel Patient-Friendly Techniques for the Treatment of Diabetes.

Author information

Department of Pharmacy, Faculty of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan. India.
Rungta College of Pharmaceutical Sciences and Research, Kohka-Kurud Road, Bhilai, Chhattisgarh. India.
epartment of Pharmacy, Birla Institute of Technology and Science, Pilani (BITS-PILANI), Pilani Campus, Rajasthan. India.
Department of Biotechnology, Faculty of Biotechnology, Birla Institute of Technology and Science, Pilani (BITS-PILANI). United Arab Emirates.
University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh. India.



Diabetes is one of the most common chronic metabolic disorder which affect the quality of human life worldwide. As per the WHO report, between 1980 to 2014, the number of diabetes patient increases from 108 million to 422 million, with a global prevalence rate of 8.5% per year. Diabetes is the prime reason behind various other diseases like kidney failure, stroke, heart disorders, glaucoma, etc. It is recognized as the seventh leading cause of death throughout the world. The available therapies are painful (insulin injections) and inconvenient due to higher dosing frequency. Thus, to find out a promising and convenient treatment, extensive investigations are carried out globally by combining novel carrier system (like microparticle, microneedle, nanocarrier, microbeads etc.) and delivery devices (insulin pump, stimuli-responsive device, inhalation system, bioadhesive patch, insulin pen etc.) for more precise diagnosis and painless or less invasive treatment of disease.


The review article is made with an objective to compile information about various upcoming and existing modern technologies developed to provide greater patient compliance and reduce the undesirable side effect of the drug. These devices evade the necessity of daily insulin injection and offer a rapid onset of action, which sustained for a prolonged duration of time to achieve a better therapeutic effect.


Despite numerous advantages, various commercialized approaches like Afrezza (inhalation insulin) face failure in recent years. Such results call for more potential work to develop a promising system. The novel approaches range from the delivery of non-insulin blood glucose lowering agents to insulin-based therapy with minimal invasion are highly desirable.


Diabetes; Novel drug delivery; insulin; insulin pen; microparticle ; non-invasive

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center